Informations relatives au nombre total de droits de vote et d’actions composant le capital
Filed with Euronext · · 1 page · French
Summary by 6ix AI
This filing provides information regarding the total number of voting rights and shares comprising the capital of OSE Immunotherapeutics SA as of a specific date. It includes details about newly issued shares related to a financing arrangement with IRIS Capital Investment. The document is intended to inform shareholders about the company's capital structure and voting rights.
Written in English by 6ix AI from the company’s French-language filing. How 6ix writes summaries
OSE Immunotherapeutics SA on 6ix
Earlier from OSE Immunotherapeutics
- OSE Immunotherapeutics Reports Results of its 2026 Annual General Meeting
- Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting
- OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
- OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
- OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
Later from OSE Immunotherapeutics
- OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
- OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux
- OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients
- OSE Immunotherapeutics annonce la présentation des principaux résultats de l'étude de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules au Congrès 2026 de l’ESMO
- OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
Follow OSE Immunotherapeutics into a list and get an email when it puts out news.
Follow OSE Immunotherapeutics